Addressing cancer disparities in nigeria through immuno-oncology research - the nola program

Ended Project Grant Awarded Last action

Award ID
P20CA290448
Recipient
Awarding agency
Obligated
$2,149,596

Award facts

Assistance listing
93.399 Cancer Control
Completion date
Place of performance
New York, NY 10065, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Overall in the US and other high-income countries, immunotherapy is transforming the management of some cancers, including colorectal cancer (CRC). However, immunotherapy is not widely available to patients in low- and middle-income countries (LMICS) who might benefit the most. Our collaborations in sub-saharan africa over the past 10 years have highlighted disparities for nigerian patients diagnosed with CRC - 53% of nigerian CRC patients will DIE within a year of diagnosis, compared to 17% in the US - and incidence in nigeria is rising. Interestingly, in work to understand the biological underpinnings of these disparities, we found a 3-fold higher rate of the immunogenic MSI-H (high microsatellite instability) phenotype in nigerian compared to US CRC, suggesting a unique opportunity to address CRC disparities in nigeria with immunotherapy. Based on these findings, we are separately initiating the first prospective trial of immunotherapy for MSI-H CRC in sub-saharan africa. While promising, our work in this area has illuminated the severe lack of immuno-oncology data from nigerian patients (and other lmic populations) at all scientific levels. Bringing the promise of immunotherapy to these populations requires a contextual understanding of CRC immunobiology, biomarkers to efficiently and cost-effectively select patients most likely to benefit from treatment, and regional immuno-oncology experts with knowledge of immunotherapy and immune-related side effects. To address these needs, we will establish the nigerian immuno-oncology research (NOLA) program, with a goal to synergize our existing strengths in global cancer disparities research and immuno-oncology that have, until now, lacked an integrated focus and coordination. Specifically, in this P20 project, we will unite a multi-disciplinary group to 1. Develop pilot data to guide future studies investigating the tumor microenvironment of nigerian CRC; 2. Integrate a multi-disciplinary team and research projects focused on immuno-oncology in nigerian and US cancer patients; and 3. Develop biobanks and databases of nigerian CRC to support future immuno-oncology research. By the end of the project period, we will have generated the preliminary data, resources, infrastructure, and program plan to support a robust multi-disciplinary, collaborative immuno-oncology research to address health disparities between nigerian and US patients with CRC beyond the P20.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $31,456
Amendment $31,456
Amendment $31,456
Amendment $87,066
Amendment $87,066
Amendment $87,066
Amendment $214,919
Amendment $214,919
Amendment $214,919
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $383,091
Amendment $383,091
Original award $383,091
Show all 29

Subawards

Subrecipient Amount Awarded
College Of Medicine, University Of Lagos Professor Abdulkareem, pathologist and research at the University of Lagos Hospital (LUTH), is a member of ARGO and oversees ARGO colorectal cancer (CRC) data… $31,456
Obafemi Awolowo University Olusegun Alatise will work closely with Drs. Kingham and Sanchez-Vega. He will lead activities in Nigeria and efforts toward fostering and strengthening… $87,066
College Of Medicine, University Of Lagos Professor Abdulkareem, pathologist and research at the University of Lagos Hospital (LUTH), is a member of ARGO and oversees ARGO colorectal cancer (CRC) data… $33,928
Obafemi Awolowo University Olusegun Isaac Alatise will oversee research activities at OAU. He will be responsible for submission of review documents to the Hospital Ethics and Research… $60,395

Quick answers

Who received award P20CA290448?

P20CA290448 was awarded to Sloan-Kettering Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on September 16, 2024.

How much is award P20CA290448 worth?

$2,149,596 has been obligated on P20CA290448.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login